ORKA's Losses Widen Amid Increased R&D, Bolstered by $180M PIPE

TL;DR

**ORKA is burning cash faster with higher R&D, but fresh capital infusions keep the lights on for now.**

AI Summary

Oruka Therapeutics, Inc. (ORKA) reported a net loss of $30.277 million for the three months ended September 30, 2025, an increase from $28.623 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $75.850 million, compared to $57.943 million for the period from inception (February 6, 2024) to September 30, 2024. Research and development expenses rose to $28.988 million for the three months ended September 30, 2025, up from $25.691 million in the prior year, and to $73.000 million for the nine months, from $49.557 million. General and administrative expenses also increased to $5.117 million for the quarter and $14.620 million for the nine months. The company's cash and cash equivalents increased to $91.253 million as of September 30, 2025, from $61.575 million at December 31, 2024, largely due to $170.017 million in net cash provided by financing activities, including $169.908 million from PIPE Financings. Total assets grew to $509.251 million from $396.019 million, while total liabilities increased to $22.460 million from $13.798 million. The company completed a reverse recapitalization on August 29, 2024, and subsequently raised capital through a 2024 PIPE Financing of approximately $188.7 million and a 2025 PIPE Financing of $180.000 million.

Why It Matters

Oruka Therapeutics' widening net losses and increased R&D spending signal a company in aggressive development, typical for a clinical-stage biopharmaceutical firm. For investors, the significant capital raises, including the $180 million 2025 PIPE Financing, are crucial as they provide a runway for ongoing drug development, particularly for psoriasis and inflammatory indications, but also dilute existing shareholders. Employees benefit from continued funding for research, while customers and the broader market await potential new therapies. The competitive landscape in immunology is intense, making efficient use of this capital vital for ORKA to differentiate its biologics.

Risk Assessment

Risk Level: high — The company reported a net loss of $75.850 million for the nine months ended September 30, 2025, and an accumulated deficit of $159.574 million, indicating significant ongoing losses. While cash and cash equivalents increased to $91.253 million, this is largely due to financing activities, and the company continues to use substantial cash in operations, with $65.616 million used in operating activities for the nine months ended September 30, 2025.

Analyst Insight

Investors should closely monitor Oruka Therapeutics' clinical trial progress and future financing needs. While recent PIPE financings provide a capital cushion, the increasing R&D expenses and net losses suggest a high-risk, high-reward profile typical of early-stage biotechs. Consider this a speculative investment based on pipeline potential, not current profitability.

Financial Highlights

debt To Equity

0.05

revenue

N/A

operating Margin

N/A

total Assets

$509.251M

total Debt

$22.460M

net Income

-$75.850M

eps

N/A

gross Margin

N/A

cash Position

$91.253M

revenue Growth

N/A

Key Numbers

• $75.850M — Net Loss (9 months) (Increased from $57.943M in prior year period, indicating widening losses.)
• $91.253M — Cash and Cash Equivalents (Increased from $61.575M at Dec 31, 2024, providing liquidity.)
• $180.000M — 2025 PIPE Financing Proceeds (Significant capital raise to fund operations and R&D.)
• $73.000M — Research and Development (9 months) (Increased from $49.557M, reflecting intensified drug development.)
• $159.574M — Accumulated Deficit (Grew from $83.724M, highlighting continued unprofitability.)
• 48,409,232 — Common Stock Outstanding (As of October 31, 2025, indicating potential dilution from financing activities.)
• $65.616M — Net Cash Used in Operating Activities (9 months) (Increased from $39.019M, showing higher cash burn.)
• $509.251M — Total Assets (Increased from $396.019M, primarily due to cash from financing.)

Key Players & Entities

• Oruka Therapeutics, Inc. (company) — registrant
• ARCA biopharma, Inc. (company) — former name of registrant
• SEC (regulator) — U.S. Securities and Exchange Commission
• $30.277 million (dollar_amount) — net loss for three months ended September 30, 2025
• $75.850 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $91.253 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $180.000 million (dollar_amount) — proceeds from 2025 PIPE Financing
• $28.988 million (dollar_amount) — research and development expenses for three months ended September 30, 2025
• $159.574 million (dollar_amount) — accumulated deficit as of September 30, 2025
• The Nasdaq Global Market (company) — exchange where ORKA is registered

FAQ

Risk Factors

• Significant Accumulated Deficit and Cash Burn [high — financial]: The company reported an accumulated deficit of $159.574 million as of September 30, 2025, a substantial increase from $83.724 million at December 31, 2024. Furthermore, net cash used in operating activities for the nine months ended September 30, 2025, was $65.616 million, up from $39.019 million in the prior year period. This indicates a widening cash burn rate, which could pose a future liquidity risk if not offset by continued financing.
• Dependence on Financing Activities [high — financial]: Oruka Therapeutics' substantial increase in cash position, from $61.575 million at December 31, 2024, to $91.253 million at September 30, 2025, was primarily driven by $170.017 million in net cash provided by financing activities, including significant PIPE financings ($188.7 million in 2024 and $180.0 million in 2025). This heavy reliance on external capital raises concerns about future funding needs and potential dilution.
• Increasing Research and Development Expenses [medium — operational]: Research and development expenses have significantly increased, rising to $28.988 million for the three months ended September 30, 2025, from $25.691 million in the prior year, and to $73.000 million for the nine months ended September 30, 2025, from $49.557 million. While this reflects investment in drug development, it also contributes to the company's growing net losses and cash burn.
• Widening Net Losses [high — financial]: The company reported a net loss of $30.277 million for the three months ended September 30, 2025, an increase from $28.623 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $75.850 million, compared to $57.943 million for the comparable period in 2024. This trend of increasing losses, coupled with rising operating expenses, highlights the company's ongoing unprofitability.
• Marketable Securities Fluctuation [medium — financial]: Marketable securities, current, decreased from $314.073 million at December 31, 2024, to $257.902 million at September 30, 2025. Conversely, long-term marketable securities increased from $18.069 million to $151.763 million. This shift suggests a potential reallocation of assets or market value changes impacting liquidity and investment strategy.
• Growth in General and Administrative Expenses [medium — operational]: General and administrative expenses have also seen an increase, reaching $5.117 million for the three months ended September 30, 2025, up from $3.758 million in the prior year, and $14.620 million for the nine months, up from $8.248 million. This rise in G&A costs, alongside R&D, contributes to the overall increase in operating expenses.

Industry Context

Oruka Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on drug development. The industry is characterized by long development cycles, high failure rates, and significant regulatory hurdles. Success often depends on substantial R&D investment, strategic partnerships, and successful capital raises to fund clinical trials and commercialization.

Regulatory Implications

As a biotechnology company, Oruka Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory pathways can significantly impact development timelines and market access. Compliance with evolving regulations is critical for continued operation and product approval.

What Investors Should Do

1. Monitor R&D spend and pipeline progress
2. Evaluate future financing needs and dilution risk
3. Analyze cash burn rate and runway
4. Assess the widening net loss trend

Key Dates

• 2024-08-29: Reverse Recapitalization Completed — This event fundamentally restructured the company, paving the way for subsequent financing activities and public market access.
• 2024-12-31: Year-End Financial Position — Established baseline for key financial metrics including cash ($61.575M), total assets ($396.019M), and accumulated deficit ($83.724M) at the start of the reporting period.
• 2025-09-30: Quarterly Financial Reporting Date — Represents the most recent financial snapshot, showing increased cash ($91.253M), higher total assets ($509.251M), and a significantly larger accumulated deficit ($159.574M).
• 2025-09-30: End of Nine-Month Reporting Period — Key period for analyzing operational performance, showing a net loss of $75.850M and R&D expenses of $73.000M.

Glossary

PIPE Financing

Private Investment in Public Equity. A transaction where institutional investors purchase securities directly from a publicly traded company. (Oruka Therapeutics has raised substantial capital through PIPE financings, which are critical for funding its operations and development activities.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a negative retained earnings balance. (Indicates the company's historical unprofitability, with a significant increase to $159.574 million as of September 30, 2025.)

Reverse Recapitalization

A transaction where a private company merges with or acquires a public shell company, effectively becoming a public entity without a traditional IPO. Often involves a significant change in control and equity structure. (Oruka Therapeutics underwent this process on August 29, 2024, which is a key event in its financial history and path to capital raising.)

Operating lease right-of-use assets

An asset recognized under ASC 842 for the right to use a leased asset over the lease term. (Represents the company's commitment to leased assets, with a balance of $1.969 million as of September 30, 2025.)

Common stock warrant liability

A liability recorded for warrants issued that may require the company to issue stock under certain conditions, often related to financing or acquisition activities. (The company has a related party common stock warrant liability of $9.684 million as of September 30, 2025, which could impact future equity structure.)

Additional paid-in capital

The amount investors have paid for stock above its par or stated value. It reflects capital raised from issuing stock. (This account has grown significantly to $643.201 million as of September 30, 2025, primarily due to the capital raised from PIPE financings.)

Year-Over-Year Comparison

Compared to the prior year period (inception to Sept 30, 2024), Oruka Therapeutics has seen a significant increase in its net loss, rising from $57.943 million to $75.850 million for the nine-month period. This widening loss is driven by a substantial increase in Research and Development expenses, which grew from $49.557 million to $73.000 million. While total assets have grown considerably to $509.251 million, largely due to successful capital raises, the company's cash burn from operations has also accelerated, with net cash used increasing from $39.019 million to $65.616 million.

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share ORKA The Nasdaq Global Market

Filing Documents

• ea0262412-10q_oruka.htm (10-Q) — 1405KB
• ea026241201ex31-1_oruka.htm (EX-31.1) — 10KB
• ea026241201ex31-2_oruka.htm (EX-31.2) — 10KB
• ea026241201ex32-1_oruka.htm (EX-32.1) — 6KB
• 0001213900-25-109182.txt ( ) — 7383KB
• orka-20250930.xsd (EX-101.SCH) — 71KB
• orka-20250930_cal.xml (EX-101.CAL) — 32KB
• orka-20250930_def.xml (EX-101.DEF) — 341KB
• orka-20250930_lab.xml (EX-101.LAB) — 585KB
• orka-20250930_pre.xml (EX-101.PRE) — 364KB
• ea0262412-10q_oruka_htm.xml (XML) — 1037KB

Financial Information

PART I. Financial Information Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32

Other Information

PART II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 62 Item 3. Defaults Upon Senior Securities 62 Item 4. Mine Safety Disclosures 62 Item 5. Other Information 62 Item 6. Exhibits 63

- Financial Information

Part I - Financial Information

Financial Statements

Item 1. Financial Statements ORUKA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share data) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 91,253 $ 61,575 Marketable securities, current 257,902 314,073 Prepaid expenses and other current assets 6,008 1,221 Total current assets 355,163 376,869 Marketable securities, long-term 151,763 18,069 Property and equipment, net 253 162 Operating lease right-of-use assets 1,969 876 Other non-current assets 103 43 Total assets $ 509,251 $ 396,019 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,208 $ 3,462 Accrued expenses and other current liabilities 8,648 3,346 Operating lease liability, current 419 213 Related party common stock warrant liability 9,684 — Related party accounts payable and other current liabilities 8 6,022 Total current liabilities 20,967 13,043 Operating lease liability, non-current 1,493 755 Total liabilities 22,460 13,798 Commitments and contingencies (Note 11) Stockholders' equity: Series B non-voting convertible preferred stock, $ 0.001 par value; 251,504 shares authorized as of September 30, 2025 and December 31, 2024; 137,138 shares issued and outstanding as of September 30, 2025 and December 31, 2024 2,931 2,931 Common stock, $ 0.001 par value; 545,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 48,384,150 and 37,440,510 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 48 37 Additional paid-in capital 643,201 463,018 Accumulated other comprehensive income (loss) 185 ( 41 ) Accumulated deficit ( 159,574 ) ( 83,724 ) Total stockholders' equity 486,791 382,221 Total liabilities and stockholders' equity $ 509,251 $ 396,019 The accompanying notes are an integral part of these condensed consolid

View Full Filing

View this 10-Q filing on SEC EDGAR